Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 532

Similar articles for PubMed (Select 21722179)

1.

Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.

Ladero JM, Martin EG, Fernández C, Carballo M, Devesa MJ, Martínez C, Suárez A, Díaz-Rubio M, Agúndez JA.

J Gastroenterol Hepatol. 2012 Feb;27(2):279-85. doi: 10.1111/j.1440-1746.2011.06834.x.

PMID:
21722179
2.

Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.

Hayashi K, Katano Y, Honda T, Ishigami M, Itoh A, Hirooka Y, Ishikawa T, Nakano I, Yoshioka K, Toyoda H, Kumada T, Goto H.

Liver Int. 2011 Oct;31(9):1359-65. doi: 10.1111/j.1478-3231.2011.02571.x. Epub 2011 Jun 23.

PMID:
21745312
3.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
4.

Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy.

Liu CH, Liang CC, Liu CJ, Tseng TC, Lin CL, Yang SS, Su TH, Hsu SJ, Lin JW, Chen JH, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2012;17(3):477-84. doi: 10.3851/IMP2026. Epub 2011 Dec 20.

PMID:
22301466
5.

Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.

Kawaoka T, Takahashi S, Takaki S, Hiramatsu A, Waki K, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Onoe T, Tashiro H, Ohdan H, Chayama K.

J Gastroenterol Hepatol. 2012 Sep;27(9):1467-72. doi: 10.1111/j.1440-1746.2012.07129.x.

PMID:
22432893
6.

IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.

Martínez-Gómez LE, Chávez-Tapia NC, Burguete-García AI, Aguilar-Olivos N, Madrid-Marina V, Román-Bahena M, Orbe-Orihuela C, Misael U, Méndez-Sánchez N.

Ann Hepatol. 2012 Nov-Dec;11(6):876-81.

7.

Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?

Garcia RF, Moreira S, de Araújo Ramos AL, Ferreira LE, de Mattos AA, Tovo CV, Nader LA, Ramos JA, Rondinelli E, de Jesus Dominici A, Garcia CE, de Souza Leite Pinho M, Brandão-Mello CE, Villela-Nogueira CA, de França PH.

World J Gastroenterol. 2013 Nov 14;19(42):7399-404. doi: 10.3748/wjg.v19.i42.7399.

8.

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR; SPRINT-2 and RESPOND-2 Investigators.

Gastroenterology. 2012 Sep;143(3):608-18.e1-5. doi: 10.1053/j.gastro.2012.05.011. Epub 2012 May 21.

PMID:
22626609
9.

Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.

Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, Martínez A, Gadano A, Mandó OG, Silva MO.

Ann Hepatol. 2011 Oct-Dec;10(4):452-7.

10.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.

Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.

Gut. 2011 Feb;60(2):261-7. doi: 10.1136/gut.2010.223495. Epub 2010 Nov 10.

PMID:
21068134
11.

A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.

Halfon P, Bourliere M, Ouzan D, Maor Y, Renou C, Wartelle C, Pénaranda G, Tran A, Botta D, Oules V, Castellani P, Portal I, Argiro L, Dessein A.

Eur J Gastroenterol Hepatol. 2011 Oct;23(10):931-5. doi: 10.1097/MEG.0b013e328349d0ef.

PMID:
21900787
12.

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.

Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.

J Hepatol. 2012 Sep;57(3):534-40. doi: 10.1016/j.jhep.2012.04.027. Epub 2012 May 18.

PMID:
22613000
13.

IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.

Fattovich G, Covolo L, Bibert S, Askarieh G, Lagging M, Clément S, Malerba G, Pasino M, Guido M, Puoti M, Gaeta GB, Santantonio T, Raimondo G, Bruno R, Bochud PY, Donato F, Negro F; ITAHEC Study Group.

Aliment Pharmacol Ther. 2011 May;33(10):1162-72. doi: 10.1111/j.1365-2036.2011.04635.x. Epub 2011 Mar 28.

14.

IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.

Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T.

World J Gastroenterol. 2012 Sep 21;18(35):4892-7.

15.

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.

Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS.

PLoS One. 2011 Mar 30;6(3):e18322. doi: 10.1371/journal.pone.0018322.

16.

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.

Sinn DH, Kim YJ, Lee ST, Gwak GY, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW.

J Gastroenterol Hepatol. 2011 Sep;26(9):1374-9. doi: 10.1111/j.1440-1746.2011.06744.x.

PMID:
21501223
17.

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K.

J Viral Hepat. 2011 Jul;18(7):e325-31. doi: 10.1111/j.1365-2893.2010.01425.x. Epub 2011 Jan 13.

PMID:
21692944
18.

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR.

Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.

19.

Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.

De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, De Francesco R, Prati GM, D'Ambrosio R, Cheroni C, Donato MF, Colombo M.

Hepatology. 2012 Feb;55(2):336-42. doi: 10.1002/hep.24683. Epub 2012 Jan 3.

PMID:
21932415
20.

Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.

Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH.

Gene. 2012 Oct 1;507(1):27-35. doi: 10.1016/j.gene.2012.07.026. Epub 2012 Jul 25.

PMID:
22842190
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk